December 2023 in “Revista Urología Colombiana / Colombian Urology Journal” More research is needed to find effective treatments for sickle cell disease-related priapism.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
8 citations
,
November 1978 in “British journal of dermatology/British journal of dermatology, Supplement” Cyproterone acetate can effectively treat idiopathic hirsutism, but ethinyl oestradiol and lynoestrenol may not always reduce hair growth.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
11 citations
,
July 2019 in “The Journal of Sexual Medicine” Spironolactone might cause painful intercourse and decreased sexual arousal in women.
1 citations
,
January 1979 in “International Journal of Dermatology” Cyproterone acetate effectively treats hirsutism and related conditions.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
April 2011 in “Reactions Weekly” 63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
66 citations
,
January 2008 in “Pharmacology Biochemistry and Behavior” AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
1 citations
,
October 2009 in “Current psychiatry” Choose treatments for sex offenders based on individual needs, using hormonal and nonhormonal options to reduce sexual drive.
January 2025 in “Dermatology and Therapy” Hormonal therapies effectively treat acne and improve quality of life.
58 citations
,
July 1974 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Cyproterone acetate combined with ethinyl estradiol significantly reduced hirsutism in women.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
19 citations
,
August 2023 in “Journal of Dermatological Treatment” Abrocitinib may effectively treat stubborn alopecia universalis.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.